Journal
LANCET INFECTIOUS DISEASES
Volume 12, Issue 3, Pages 240-248Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(11)70318-8
Keywords
-
Categories
Funding
- Medical Research Council [MC_U117512723, MC_U117512708] Funding Source: Medline
- MRC [MC_U117512723, MC_U117512708] Funding Source: UKRI
- Medical Research Council [MC_U117512708, MC_U117512723] Funding Source: researchfish
Ask authors/readers for more resources
Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available